Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans

First physiologically based pharmacokinetic (PBPK) model of DMT and harmine interactions from ayahuasca, developed using rat and human data. Accurately predicts plasma concentration-time profiles and MAO inhibition dynamics. Provides a framework for dose optimization in clinical settings.